褪黑素
失眠症
人文学科
医学
睡眠障碍
精神科
睡眠(系统调用)
注意缺陷多动障碍
内分泌学
内科学
心理学
妇科
哲学
计算机科学
操作系统
作者
Juan José Poza,Montserrat Pujol,J.J. Ortega-Albás,Odile Romero
出处
期刊:Neurología
[Elsevier BV]
日期:2020-09-18
卷期号:37 (7): 575-585
被引量:83
标识
DOI:10.1016/j.nrleng.2018.08.004
摘要
Melatonin is the main hormone involved in the control of the sleep-wake cycle. It is easily synthesisable and can be administered orally, which has led to interest in its use as a treatment for insomnia. Moreover, as production of the hormone decreases with age, in inverse correlation with the frequency of poor sleep quality, it has been suggested that melatonin deficit is at least partly responsible for sleep disorders. Treating this age-related deficit would therefore appear to be a natural way of restoring sleep quality, which is lost as patients age. However, despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy. Furthermore, the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined. This review addresses the physiology of melatonin, the different pharmaceutical preparations, and data on its clinical usefulness.
科研通智能强力驱动
Strongly Powered by AbleSci AI